Dr. Richmond received her Bachelor of Science degree from Northeast Louisiana University, her Master of Natural Sciences degree from Louisiana State University and her Ph.D. in Developmental Biology at Emory University in 1979. She conducted postdoctoral research in Tumor Biology at Emory, and then joined the faculty there, rising to the rank of associate professor of Medicine before moving to Vanderbilt in 1989 as tenured associate professor of Cell Biology and Medicine and as a research career scientist at the U.S. Department of Veterans Affairs Nashville campus. She was promoted to full professor in 1995, and she was appointed professor and vice chair of the Department of Cancer Biology in 2000.

Dr. Richmond is internationally known for her research on chemokines, small “chemotactic” proteins that attract inflammatory cells. She was the first to demonstrate that a chemokine can regulate tumor growth. Her early research involved purification and sequencing of one of the first known chemokines, CXCL1, and her lab played a major role in characterization of the role of its receptor, CXCR2, in leukocyte trafficking, inflammation, angiogenesis, wound healing and tumor progression. She and her colleagues helped elucidate the role that inhibitor of kappa-beta kinaseβ (IKKβ), an activator of the transcription factor NF-κB, plays in chemokine expression and melanoma cell survival, suggesting that IKKβ may be a potential target for melanoma therapy. T

Dr. Richmond’s body of work -- more than 180 publications cited by other scientists more than 14,300 times – has shed light on how the inflammatory process, combined with other genetic and environmental factors, contributes to tumor progression and metastasis. A goal of her research is the advancement of “personalized cancer therapy” -- determining which genes are mutated or amplified in individual tumors and delivering drugs that specifically inhibit the activity of those genes. Antagonizing chemokine receptors may provide new therapeutic options. Toward that end, she and her colleagues are working to learn more about the effects of therapy on the tumor microenvironment, including the development of drug resistance.

The Richmond laboratory currently investigates the intracellular signals that are important in the tumor microenvironment and in the pre-metastatic niche to reduce the establishment of metastatic lesions. Recently, following basic discoveries on the pathways involved in melanoma progression, her group developed translational studies using patient derived xenograft models to explore new therapeutic approaches for melanoma. They demonstrated that combining aurora kinase A inhibitors with MDM2 antagonists markedly inhibit melanoma tumor growth, using patient derived xenograft models as well as immunocompetent mouse models. They have also shown that while targeted deletion of IKKβ in melanoma cells blocks mutant Ras mediated transformation, targeted deletion of IKKβ in myeloid cells leads to enhanced tumor growth and metastasis for melanoma tumors. Surprisingly, we have shown that systemic inhibition of NF-κB inhibits growth of mutant Ras driven melanoma tumors. She now plans to extend initial studies combining Aurora Kinase and MDM2 inhibitors to evaluate an even more promising combination therapy, CDK4/6 inhibitors and MDM2 antagonists. They will develop animal models and utilize in vitro and in vivo imaging techniques to characterize the mechanism by which antagonists of cell cycle combined with reagents that enhance apoptosis may synergize to improve treatment for cancer. Her laboratory has worked to determine how inflammatory signals from tumors induce the chronic and elevated expression of chemokines and/or their receptors to recruit leukocytes that enhance or inhibit tumorigenesis and metastasis. They are experienced in the characterization of leukocyte interaction with the tumor microenvironment and in identification of subsets of these cells within the tumor using FACS. Moreover, we are currently characterizing the role of a number of small molecule inhibitors that affect melanoma tumor growth and metastasis using patient derived xenografts. She and her group recently determined the role of CXCR4 in mediating estrogen independent growth and metastasis of breast cancer and have shown that inhibition of CXCR2 and CXCR4 can alter the leukocyte composition of the pre-metastatic niche. She has an outstanding group of collaborators and access to phenomenal infrastructure for acquiring patients, obtaining informed consent, tissue collection, patient follow-up, and access to patients in clinical trials.

Dr. Richmond also is deeply committed to education. She has mentored more than 50 undergraduates, graduate students and postdoctoral fellows. She served as assistant dean of Biomedical Research Education and Training from 2005 to 2010, initiated the Master's Degree in Laboratory Science Program at Vanderbilt, and organized the first Chemokine and Chemokine Gordon Research Conference, which remains enormously popular. She is Director of the Program in Cancer Biology and Associate Director of Basic Education for the Vanderbilt Ingram Cancer Center.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A (2020) Clin Cancer Res 26(14): 3803-3818
    › Primary publication · 32234759 (PubMed) · PMC7367743 (PubMed Central)
  2. Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. Ou YC, Wen X, Johnson CA, Shae D, Ayala OD, Webb JA, Lin EC, DeLapp RC, Boyd KL, Richmond A, Mahadevan-Jansen A, Rafat M, Wilson JT, Balko JM, Tantawy MN, Vilgelm AE, Bardhan R (2020) ACS Nano 14(1): 651-663
    › Primary publication · 31851488 (PubMed) · PMC7391408 (PubMed Central)
  3. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A (2019) Sci Transl Med 11(505)
    › Primary publication · 31413145 (PubMed) · PMC7584132 (PubMed Central)
  4. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, Richmond A (2019) Invest Ophthalmol Vis Sci 60(4): 954-964
    › Primary publication · 30882851 (PubMed) · PMC6424472 (PubMed Central)
  5. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Vilgelm AE, Richmond A (2019) Front Immunol : 333
    › Primary publication · 30873179 (PubMed) · PMC6400988 (PubMed Central)
  6. Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A (2018) Cancer Immunol Res 6(10): 1186-1198
    › Primary publication · 30108045 (PubMed) · PMC6170679 (PubMed Central)
  7. Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment. Rogers M, Sobolik T, Schaffer DK, Samson PC, Johnson AC, Owens P, Codreanu SG, Sherrod SD, McLean JA, Wikswo JP, Richmond A (2018) Biomicrofluidics 12(3): 034102
    › Primary publication · 29774083 (PubMed) · PMC5938175 (PubMed Central)
  8. Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, LaNeve DC, Williams PE, Boyd KL, Reyzer ML, Lindsley CW, Friedman DL, Richmond A (2018) Invest Ophthalmol Vis Sci 59(1): 446-454
    › Primary publication · 29368001 (PubMed) · PMC5783625 (PubMed Central)
  9. MDM2 Antagonists Counteract Drug-Induced DNA Damage. Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A (2017) EBioMedicine : 43-55
    › Primary publication · 29030058 (PubMed) · PMC5652019 (PubMed Central)
  10. Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging. Sobolik T, Su YJ, Ashby W, Schaffer DK, Wells S, Wikswo JP, Zijlstra A, Richmond A (2016) Intravital 5(1): e1125562
    › Primary publication · 28243517 (PubMed) · PMC5226013 (PubMed Central)
  11. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. Lavender N, Yang J, Chen SC, Sai J, Johnson CA, Owens P, Ayers GD, Richmond A (2017) BMC Cancer 17(1): 88
    › Primary publication · 28143493 (PubMed) · PMC5286656 (PubMed Central)
  12. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhal A, Richmond A, Shanker A (2017) Oncotarget 8(5): 8604-8621
    › Primary publication · 28052005 (PubMed) · PMC5352426 (PubMed Central)
  13. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A (2017) Clin Cancer Res 23(13): 3371-3384
    › Primary publication · 28003307 (PubMed) · PMC5479746 (PubMed Central)
  14. Micrometastatic Dormancy in Uveal Melanoma: A Comprehensive Review of the Evidence, Mechanisms, and Implications for Future Adjuvant Therapies. Nichols EE, Richmond A, Daniels AB (2017) Int Ophthalmol Clin 57(1): 1-10
    › Primary publication · 27898609 (PubMed)
  15. Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. Saxon JA, Sherrill TP, Polosukhin VV, Sai J, Zaynagetdinov R, McLoed AG, Gulleman PM, Barham W, Cheng DS, Hunt RP, Gleaves LA, Richmond A, Young LR, Yull FE, Blackwell TS (2016) Oncoimmunology 5(6): e1168549
    › Primary publication · 27471643 (PubMed) · PMC4938365 (PubMed Central)
  16. Combinatorial approach to cancer immunotherapy: strength in numbers. Vilgelm AE, Johnson DB, Richmond A (2016) J Leukoc Biol 100(2): 275-90
    › Primary publication · 27256570 (PubMed) · PMC6608090 (PubMed Central)
  17. Using avatars to win the fight over BRAF inhibitor resistance. Vilgelm AE, Richmond A (2016) Pigment Cell Melanoma Res 29(4): 398-9
    › Primary publication · 27185579 (PubMed) · PMC6750947 (PubMed Central)
  18. Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma. Nichols EE, Richmond A, Daniels AB (2016) Semin Ophthalmol 31(4): 304-9
    › Primary publication · 27128983 (PubMed) · PMC5526754 (PubMed Central)
  19. Disparities in Uveal Melanoma: Patient Characteristics. Nichols EE, Richmond A, Daniels AB (2016) Semin Ophthalmol 31(4): 296-303
    › Primary publication · 27128153 (PubMed) · PMC5441550 (PubMed Central)
  20. The role of NF-kB in modulating antitumor immunity. Richmond A, Yang J (2016) Oncoimmunology 5(1): e1005522
    › Primary publication · 26942050 (PubMed) · PMC4760307 (PubMed Central)
  21. Study of Chemotaxis and Cell-Cell Interactions in Cancer with Microfluidic Devices. Sai J, Rogers M, Hockemeyer K, Wikswo JP, Richmond A (2016) Methods Enzymol : 19-45
    › Primary publication · 26921940 (PubMed) · PMC5378165 (PubMed Central)
  22. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
    › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)
  23. Chemokine Regulation of Neutrophil Infiltration of Skin Wounds. Su Y, Richmond A (2015) Adv Wound Care (New Rochelle) 4(11): 631-640
    › Primary publication · 26543677 (PubMed) · PMC4620531 (PubMed Central)
  24. Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. Vilgelm A, Richmond A (2015) Oncoimmunology 4(8): e1009299
    › Primary publication · 26405565 (PubMed) · PMC4570092 (PubMed Central)
  25. Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. Pawlikowski JS, Brock C, Chen SC, Al-Olabi L, Nixon C, McGregor F, Paine S, Chanudet E, Lambie W, Holmes WM, Mullin JM, Richmond A, Wu H, Blyth K, King A, Kinsler VA, Adams PD (2015) J Invest Dermatol 135(11): 2902
    › Primary publication · 26178707 (PubMed)
  26. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2015) Clin Cancer Res 21(23): 5338-48
    › Primary publication · 26152738 (PubMed) · PMC4668227 (PubMed Central)
  27. LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex. Duvall-Noelle N, Karwandyar A, Richmond A, Raman D (2016) Oncogene 35(9): 1122-33
    › Primary publication · 25982273 (PubMed) · PMC4651668 (PubMed Central)
  28. Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. Pawlikowski JS, Brock C, Chen SC, Al-Olabi L, Nixon C, McGregor F, Paine S, Chanudet E, Lambie W, Holmes WM, Mullin JM, Richmond A, Wu H, Blyth K, King A, Kinsler VA, Adams PD (2015) J Invest Dermatol 135(8): 2093-2101
    › Primary publication · 25815427 (PubMed) · PMC4539947 (PubMed Central)
  29. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A (2015) Cancer Res 75(1): 181-93
    › Primary publication · 25398437 (PubMed) · PMC4286469 (PubMed Central)
  30. Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment. Hockemeyer K, Janetopoulos C, Terekhov A, Hofmeister W, Vilgelm A, Costa L, Wikswo JP, Richmond A (2014) Biomicrofluidics 8(4): 044105
    › Primary publication · 25379090 (PubMed) · PMC4189212 (PubMed Central)
  31. Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE, Richmond A (2014) Cancer Res 74(24): 7274-84
    › Primary publication · 25336190 (PubMed) · PMC4349570 (PubMed Central)
  32. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J (2014) Invest New Drugs 32(5): 1017-27
    › Primary publication · 24890858 (PubMed) · PMC4171216 (PubMed Central)
  33. Adaptor protein2 (AP2) orchestrates CXCR2-mediated cell migration. Raman D, Sai J, Hawkins O, Richmond A (2014) Traffic 15(4): 451-69
    › Primary publication · 24450359 (PubMed) · PMC3966550 (PubMed Central)
  34. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A (2014) Mol Biol Cell 25(5): 566-82
    › Primary publication · 24403602 (PubMed) · PMC3937084 (PubMed Central)
  35. Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. Davis TA, Vilgelm AE, Richmond A, Johnston JN (2013) J Org Chem 78(21): 10605-16
    › Primary publication · 24127627 (PubMed) · PMC3880828 (PubMed Central)
  36. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, Richmond A, Sung HJ (2013) FASEB J 27(7): 2788-98
    › Primary publication · 23568779 (PubMed) · PMC3688746 (PubMed Central)
  37. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
  38. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A, Richardson RM (2012) J Immunol 189(6): 2824-32
    › Primary publication · 22869904 (PubMed) · PMC3436986 (PubMed Central)
  39. INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D, Richmond A (2012) Cancer Res 72(18): 4682-95
    › Primary publication · 22836752 (PubMed) · PMC3459578 (PubMed Central)
  40. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W (2012) PLoS One 7(4): e35309
    › Primary publication · 22536370 (PubMed) · PMC3335021 (PubMed Central)
  41. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
  42. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Hawkins OE, Richmond A (2012) Breast Cancer Res 14(1): 103
    › Primary publication · 22293321 (PubMed) · PMC3496126 (PubMed Central)
  43. NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Thu YM, Su Y, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C, Richmond A (2012) Oncogene 31(20): 2580-92
    › Primary publication · 21963849 (PubMed) · PMC3253179 (PubMed Central)
  44. IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse". Neel NF, Sai J, Ham AJ, Sobolik-Delmaire T, Mernaugh RL, Richmond A (2011) PLoS One 6(8): e23813
    › Primary publication · 21876773 (PubMed) · PMC3158102 (PubMed Central)
  45. Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Raman D, Milatovic SZ, Milatovic D, Splittgerber R, Fan GH, Richmond A (2011) Toxicol Appl Pharmacol 256(3): 300-13
    › Primary publication · 21704645 (PubMed) · PMC3236026 (PubMed Central)
  46. Chemokine research moves on. Richmond A (2011) Exp Cell Res 317(5): 553-5
    › Primary publication · 21241691 (PubMed) · PMC3056356 (PubMed Central)
  47. Chemokines in health and disease. Raman D, Sobolik-Delmaire T, Richmond A (2011) Exp Cell Res 317(5): 575-89
    › Primary publication · 21223965 (PubMed) · PMC3063402 (PubMed Central)
  48. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME (2011) Cancer Res 71(2): 603-13
    › Primary publication · 21123450 (PubMed) · PMC3140407 (PubMed Central)
  49. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Thu YM, Richmond A (2010) Cytokine Growth Factor Rev 21(4): 213-26
    › Primary publication · 20685151 (PubMed) · PMC2939163 (PubMed Central)
  50. Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. Das ST, Rajagopalan L, Guerrero-Plata A, Sai J, Richmond A, Garofalo RP, Rajarathnam K (2010) PLoS One 5(7): e11754
    › Primary publication · 20668677 (PubMed) · PMC2909905 (PubMed Central)
  51. Bimodal analysis reveals a general scaling law governing nondirected and chemotactic cell motility. Gruver JS, Potdar AA, Jeon J, Sai J, Anderson B, Webb D, Richmond A, Quaranta V, Cummings PT, Chung CY (2010) Biophys J 99(2): 367-76
    › Primary publication · 20643054 (PubMed) · PMC2905119 (PubMed Central)
  52. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, Karin M, Richmond A (2010) J Clin Invest 120(7): 2563-74
    › Primary publication · 20530876 (PubMed) · PMC2898608 (PubMed Central)
  53. LIM and SH3 protein-1 modulates CXCR2-mediated cell migration. Raman D, Sai J, Neel NF, Chew CS, Richmond A (2010) PLoS One 5(4): e10050
    › Primary publication · 20419088 (PubMed) · PMC2856662 (PubMed Central)
  54. Chemokine modulation of the tumor microenvironment. Richmond A (2010) Pigment Cell Melanoma Res 23(3): 312-3
    › Primary publication · 20415714 (PubMed) · PMC3140344 (PubMed Central)
  55. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Lazennec G, Richmond A (2010) Trends Mol Med 16(3): 133-44
    › Primary publication · 20163989 (PubMed) · PMC2840699 (PubMed Central)
  56. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) Clin Cancer Res 16(1): 348-57
    › Primary publication · 20028756 (PubMed) · PMC3205975 (PubMed Central)
  57. The role of chemokines in intestinal inflammation and cancer. Wang D, Dubois RN, Richmond A (2009) Curr Opin Pharmacol 9(6): 688-96
    › Primary publication · 19734090 (PubMed) · PMC2787713 (PubMed Central)
  58. Monitoring NF-kappaB mediated chemokine transcription in tumorigenesis. Yang J, Richmond AJ (2009) Methods Enzymol : 347-55
    › Primary publication · 19446734 (PubMed) · PMC3140415 (PubMed Central)
  59. Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Raman D, Neel NF, Sai J, Mernaugh RL, Ham AJ, Richmond AJ (2009) Methods Enzymol : 315-30
    › Primary publication · 19446732 (PubMed) · PMC3140414 (PubMed Central)
  60. VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. Neel NF, Barzik M, Raman D, Sobolik-Delmaire T, Sai J, Ham AJ, Mernaugh RL, Gertler FB, Richmond A (2009) J Cell Sci 122(Pt 11): 1882-94
    › Primary publication · 19435808 (PubMed) · PMC2684839 (PubMed Central)
  61. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A (2009) Mol Cancer Ther 8(3): 636-47
    › Primary publication · 19276165 (PubMed) · PMC3140401 (PubMed Central)
  62. The good and the bad of chemokines/chemokine receptors in melanoma. Richmond A, Yang J, Su Y (2009) Pigment Cell Melanoma Res 22(2): 175-86
    › Primary publication · 19222802 (PubMed) · PMC2848967 (PubMed Central)
  63. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, Richmond A, Graham GJ, Segerer S, Nibbs RJ, Rot A (2009) Nat Immunol 10(1): 101-8
    › Primary publication · 19060902 (PubMed) · PMC3205989 (PubMed Central)
  64. Mouse xenograft models vs GEM models for human cancer therapeutics. Richmond A, Su Y (2008) Dis Model Mech 1(2-3): 78-82
    › Primary publication · 19048064 (PubMed) · PMC2562196 (PubMed Central)
  65. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Zaja-Milatovic S, Richmond A (2008) Histol Histopathol 23(11): 1399-407
    › Primary publication · 18785122 (PubMed) · PMC3140405 (PubMed Central)
  66. The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. Baugher PJ, Richmond A (2008) J Biol Chem 283(45): 30868-78
    › Primary publication · 18755694 (PubMed) · PMC2576544 (PubMed Central)
  67. Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. Sai J, Raman D, Liu Y, Wikswo J, Richmond A (2008) J Biol Chem 283(39): 26538-47
    › Primary publication · 18662984 (PubMed) · PMC2546539 (PubMed Central)
  68. Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. Yu Y, Su Y, Opalenik SR, Sobolik-Delmaire T, Neel NF, Zaja-Milatovic S, Short ST, Sai J, Richmond A (2008) J Leukoc Biol 84(2): 406-19
    › Primary publication · 18505935 (PubMed) · PMC2493076 (PubMed Central)
  69. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. Dhawan P, Su Y, Thu YM, Yu Y, Baugher P, Ellis DL, Sobolik-Delmaire T, Kelley M, Cheung TC, Ware CF, Richmond A (2008) J Biol Chem 283(22): 15399-408
    › Primary publication · 18347013 (PubMed) · PMC2397477 (PubMed Central)
  70. CCR9 homes metastatic melanoma cells to the small bowel. Richmond A (2008) Clin Cancer Res 14(3): 621-3
    › Primary publication · 18245518 (PubMed)
  71. Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells. Liu Y, Sai J, Richmond A, Wikswo JP (2008) Biomed Microdevices 10(4): 499-507
    › Primary publication · 18205049 (PubMed) · PMC2668251 (PubMed Central)
  72. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL (2008) Cancer Cell 13(1): 23-35
    › Primary publication · 18167337 (PubMed) · PMC2245859 (PubMed Central)
  73. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Horton LW, Yu Y, Zaja-Milatovic S, Strieter RM, Richmond A (2007) Cancer Res 67(20): 9791-9
    › Primary publication · 17942909 (PubMed) · PMC2668258 (PubMed Central)
  74. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, Robbins JB (2007) J Cutan Pathol 34(8): 593-6
    › Primary publication · 17640227 (PubMed) · PMC2665272 (PubMed Central)
  75. Role of chemokines in tumor growth. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Cancer Lett 256(2): 137-65
    › Primary publication · 17629396 (PubMed) · PMC2065851 (PubMed Central)
  76. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Schutyser E, Su Y, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J, Richmond A (2007) Eur Cytokine Netw 18(2): 59-70
    › Primary publication · 17594938 (PubMed) · PMC2665278 (PubMed Central)
  77. CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Ueda Y, Su Y, Richmond A (2007) Melanoma Res 17(2): 91-103
    › Primary publication · 17496784 (PubMed) · PMC2665270 (PubMed Central)
  78. Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1(CCMV). Miller-Kittrell M, Sai J, Penfold M, Richmond A, Sparer TE (2007) Virology 364(2): 454-65
    › Primary publication · 17433398 (PubMed) · PMC2665277 (PubMed Central)
  79. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Yang J, Pan WH, Clawson GA, Richmond A (2007) Cancer Res 67(7): 3127-34
    › Primary publication · 17409419 (PubMed) · PMC2665271 (PubMed Central)
  80. RhoB plays an essential role in CXCR2 sorting decisions. Neel NF, Lapierre LA, Goldenring JR, Richmond A (2007) J Cell Sci 120(Pt 9): 1559-71
    › Primary publication · 17405813 (PubMed) · PMC2766565 (PubMed Central)
  81. Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Yang J, Su Y, Richmond A (2007) Free Radic Biol Med 42(9): 1369-80
    › Primary publication · 17395010 (PubMed) · PMC1905840 (PubMed Central)
  82. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. Lee JS, Wurfel MM, Matute-Bello G, Frevert CW, Rosengart MR, Ranganathan M, Wong VW, Holden T, Sutlief S, Richmond A, Peiper S, Martin TR (2006) J Immunol 177(11): 8086-94
    › Primary publication · 17114483 (PubMed) · PMC2665269 (PubMed Central)
  83. The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. Sai J, Walker G, Wikswo J, Richmond A (2006) J Biol Chem 281(47): 35931-41
    › Primary publication · 16990258 (PubMed) · PMC2950015 (PubMed Central)
  84. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Amiri KI, Ha HC, Smulson ME, Richmond A (2006) Oncogene 25(59): 7714-22
    › Primary publication · 16799643 (PubMed) · PMC2665274 (PubMed Central)
  85. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Ueda Y, Neel NF, Schutyser E, Raman D, Richmond A (2006) Cancer Res 66(11): 5665-75
    › Primary publication · 16740704 (PubMed) · PMC2664111 (PubMed Central)
  86. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN (2006) J Exp Med 203(4): 941-51
    › Primary publication · 16567391 (PubMed) · PMC2118273 (PubMed Central)
  87. NF-kappaB activation in melanoma. Ueda Y, Richmond A (2006) Pigment Cell Res 19(2): 112-24
    › Primary publication · 16524427 (PubMed) · PMC2668252 (PubMed Central)
  88. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A (2006) Clin Cancer Res 12(3 Pt 1): 950-60
    › Primary publication · 16467110 (PubMed) · PMC2668250 (PubMed Central)
  89. Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. Su Y, Raghuwanshi SK, Yu Y, Nanney LB, Richardson RM, Richmond A (2005) J Immunol 175(8): 5396-402
    › Primary publication · 16210646 (PubMed) · PMC2668249 (PubMed Central)
  90. Chemokine receptor internalization and intracellular trafficking. Neel NF, Schutyser E, Sai J, Fan GH, Richmond A (2005) Cytokine Growth Factor Rev 16(6): 637-58
    › Primary publication · 15998596 (PubMed) · PMC2668263 (PubMed Central)
  91. Role of nuclear factor-kappa B in melanoma. Amiri KI, Richmond A (2005) Cancer Metastasis Rev 24(2): 301-13
    › Primary publication · 15986139 (PubMed) · PMC2668255 (PubMed Central)
  92. Effects of flow and diffusion on chemotaxis studies in a microfabricated gradient generator. Walker GM, Sai J, Richmond A, Stremler M, Chung CY, Wikswo JP (2005) Lab Chip 5(6): 611-8
    › Primary publication · 15915253 (PubMed) · PMC2665276 (PubMed Central)
  93. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. Schutyser E, Richmond A, Van Damme J (2005) J Leukoc Biol 78(1): 14-26
    › Primary publication · 15784687 (PubMed) · PMC2665283 (PubMed Central)
  94. The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. Sai J, Fan GH, Wang D, Richmond A (2004) J Cell Sci 117(Pt 23): 5489-96
    › Primary publication · 15479720 (PubMed) · PMC2668248 (PubMed Central)
  95. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A (2004) Cancer Res 64(14): 4912-8
    › Primary publication · 15256463 (PubMed)
  96. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Yang J, Richmond A (2004) Mol Ther 9(6): 846-55
    › Primary publication · 15194051 (PubMed) · PMC2668261 (PubMed Central)
  97. How do chemokine/chemokine receptor activations affect tumorigenesis? Richmond A, Fan GH, Dhawan P, Yang J (2004) Novartis Found Symp : 74-89; discussion 89-91, 106-11, 266-9
    › Primary publication · 15027484 (PubMed)
  98. Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. Fan GH, Lapierre LA, Goldenring JR, Sai J, Richmond A (2004) Mol Biol Cell 15(5): 2456-69
    › Primary publication · 15004234 (PubMed) · PMC404037 (PubMed Central)
  99. Fine tuning the transcriptional regulation of the CXCL1 chemokine. Amiri KI, Richmond A (2003) Prog Nucleic Acid Res Mol Biol : 1-36
    › Primary publication · 14510072 (PubMed) · PMC3140403 (PubMed Central)
  100. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Milatovic S, Nanney LB, Yu Y, White JR, Richmond A (2003) Wound Repair Regen 11(3): 213-9
    › Primary publication · 12753603 (PubMed) · PMC2667443 (PubMed Central)
  101. Cell surface heparan sulfate participates in CXCL1-induced signaling. Wang D, Sai J, Richmond A (2003) Biochemistry 42(4): 1071-7
    › Primary publication · 12549928 (PubMed) · PMC2667446 (PubMed Central)
  102. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Dhawan P, Singh AB, Ellis DL, Richmond A (2002) Cancer Res 62(24): 7335-42
    › Citation · 12499277 (PubMed)
  103. Differential regulation of CXCR2 trafficking by Rab GTPases. Fan GH, Lapierre LA, Goldenring JR, Richmond A (2003) Blood 101(6): 2115-24
    › Primary publication · 12411301 (PubMed) · PMC5365399 (PubMed Central)
  104. Nf-kappa B, chemokine gene transcription and tumour growth. Richmond A (2002) Nat Rev Immunol 2(9): 664-74
    › Primary publication · 12209135 (PubMed) · PMC2668257 (PubMed Central)
  105. Role of CXCL1 in tumorigenesis of melanoma. Dhawan P, Richmond A (2002) J Leukoc Biol 72(1): 9-18
    › Primary publication · 12101257 (PubMed) · PMC2668262 (PubMed Central)
  106. PAK1 kinase is required for CXCL1-induced chemotaxis. Wang D, Sai J, Carter G, Sachpatzidis A, Lolis E, Richmond A (2002) Biochemistry 41(22): 7100-7
    › Primary publication · 12033944 (PubMed) · PMC2668253 (PubMed Central)
  107. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A (2002) J Leukoc Biol 71(1): 141-53
    › Primary publication · 11781390 (PubMed) · PMC2665273 (PubMed Central)
  108. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. Dhawan P, Richmond A (2002) J Biol Chem 277(10): 7920-8
    › Primary publication · 11773061 (PubMed) · PMC2668260 (PubMed Central)
  109. Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. Fan GH, Yang W, Sai J, Richmond A (2002) J Biol Chem 277(8): 6590-7
    › Primary publication · 11751889 (PubMed) · PMC2665275 (PubMed Central)
  110. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Yang J, Luan J, Yu Y, Li C, DePinho RA, Chin L, Richmond A (2001) Cancer Res 61(22): 8150-7
    › Primary publication · 11719444 (PubMed)
  111. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A (2001) J Biol Chem 276(51): 47828-33
    › Citation · 11591705 (PubMed) · PMC2665282 (PubMed Central)
  112. Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors. Luan J, Furuta Y, Du J, Richmond A (2001) Cytokine 14(5): 253-63
    › Primary publication · 11444905 (PubMed) · PMC5433622 (PubMed Central)
  113. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Yang J, Richmond A (2001) Cancer Res 61(12): 4901-9
    › Primary publication · 11406569 (PubMed)
  114. The role of CDP in the negative regulation of CXCL1 gene expression. Nirodi C, Hart J, Dhawan P, Moon NS, Nepveu A, Richmond A (2001) J Biol Chem 276(28): 26122-31
    › Primary publication · 11371564 (PubMed) · PMC2665279 (PubMed Central)
  115. Phosphorylation-independent association of CXCR2 with the protein phosphatase 2A core enzyme. Fan GH, Yang W, Sai J, Richmond A (2001) J Biol Chem 276(20): 16960-8
    › Primary publication · 11278485 (PubMed) · PMC2666306 (PubMed Central)
  116. Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. Fan GH, Yang W, Wang XJ, Qian Q, Richmond A (2001) Biochemistry 40(3): 791-800
    › Primary publication · 11170396 (PubMed) · PMC2664867 (PubMed Central)
  117. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Nirodi CS, Devalaraja R, Nanney LB, Arrindell S, Russell S, Trupin J, Richmond A (2000) Wound Repair Regen 8(5): 371-82
    › Primary publication · 11115149 (PubMed) · PMC3140346 (PubMed Central)
  118. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A (2001) J Biol Chem 276(12): 9366-74
    › Citation · 11112786 (PubMed) · PMC3369623 (PubMed Central)
  119. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. Wang D, Richmond A (2001) J Biol Chem 276(5): 3650-9
    › Primary publication · 11062239 (PubMed) · PMC2676351 (PubMed Central)
  120. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM (2000) J Immunol 165(9): 5269-77
    › Primary publication · 11046061 (PubMed)
  121. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Wang D, Yang W, Du J, Devalaraja MN, Liang P, Matsumoto K, Tsubakimoto K, Endo T, Richmond A (2000) Oncogene 19(40): 4647-59
    › Primary publication · 11030154 (PubMed) · PMC2667445 (PubMed Central)
  122. Delayed wound healing in CXCR2 knockout mice. Devalaraja RM, Nanney LB, Du J, Qian Q, Yu Y, Devalaraja MN, Richmond A (2000) J Invest Dermatol 115(2): 234-44
    › Primary publication · 10951241 (PubMed) · PMC2664868 (PubMed Central)
  123. Cytokines revisited at Hilton head. Richmond A, Kaempfer R (2000) Cytokine Growth Factor Rev 11(3): 255-66
    › Primary publication · 10817967 (PubMed)
  124. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A (2000) J Leukoc Biol 67(1): 53-62
    › Primary publication · 10647998 (PubMed) · PMC2669312 (PubMed Central)
  125. Molecular cloning and characterization of a mouse gene with homology to the Duffy-antigen receptor for chemokines. Tang T, Owen JD, Du J, Walker CL, Richmond A (1998) DNA Seq 9(3): 129-43
    › Primary publication · 10520743 (PubMed)
  126. Multiple chemotactic factors: fine control or redundancy? Devalaraja MN, Richmond A (1999) Trends Pharmacol Sci 20(4): 151-6
    › Primary publication · 10322500 (PubMed)
  127. Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction. Yang W, Wang D, Richmond A (1999) J Biol Chem 274(16): 11328-33
    › Primary publication · 10196223 (PubMed)
  128. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Devalaraja MN, Wang DZ, Ballard DW, Richmond A (1999) Cancer Res 59(6): 1372-7
    › Primary publication · 10096573 (PubMed)
  129. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. Nanney LB, Skeel A, Luan J, Polis S, Richmond A, Wang MH, Leonard EJ (1998) J Invest Dermatol 111(4): 573-81
    › Primary publication · 9764835 (PubMed)
  130. Identification and characterization of an MGSA/GRO pseudogene. Shattuck-Brandt RL, Wood LD, Richmond A (1997) DNA Seq 7(6): 379-86
    › Primary publication · 9524820 (PubMed)
  131. Interruption of G protein-coupling in CXCR2 does not alter ligand binding, but eliminates ligand-activation of GTPgamma35S binding, calcium mobilization, and chemotaxis. Yang W, Schraw WP, Mueller SG, Richmond A (1997) Biochemistry 36(49): 15193-200
    › Primary publication · 9398246 (PubMed)
  132. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A (1997) J Leukoc Biol 62(5): 588-97
    › Primary publication · 9365113 (PubMed)
  133. C-X-C chemokine receptor desensitization mediated through ligand-enhanced receptor phosphorylation on serine residues. Richmond A, Mueller S, White JR, Schraw W (1997) Methods Enzymol : 3-15
    › Primary publication · 9356983 (PubMed)
  134. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R, Richmond A (1997) Int J Cancer 73(1): 94-103
    › Primary publication · 9334815 (PubMed)
  135. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Shattuck-Brandt RL, Richmond A (1997) Cancer Res 57(14): 3032-9
    › Primary publication · 9230219 (PubMed)
  136. Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor. Mueller SG, White JR, Schraw WP, Lam V, Richmond A (1997) J Biol Chem 272(13): 8207-14
    › Primary publication · 9079638 (PubMed)
  137. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF-kappa B and novel constitutive factors. Wood LD, Richmond A (1995) J Biol Chem 270(51): 30619-26
    › Primary publication · 8530498 (PubMed)
  138. Localization of MGSA/GRO protein in cutaneous lesions. Tettelbach W, Nanney L, Ellis D, King L, Richmond A (1993) J Cutan Pathol 20(3): 259-66
    › Primary publication · 8366215 (PubMed)
  139. Expression of three forms of melanoma growth stimulating activity (MGSA)/gro in human retinal pigment epithelial cells. Jaffe GJ, Richmond A, Van Le L, Shattuck RL, Cheng QC, Wong F, Roberts W (1993) Invest Ophthalmol Vis Sci 34(9): 2776-85
    › Primary publication · 8344798 (PubMed)
  140. Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells. Mueller SG, Schraw WP, Richmond A (1994) J Biol Chem 269(3): 1973-80
    › Primary publication · 8294449 (PubMed)
  141. MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. Shattuck RL, Wood LD, Jaffe GJ, Richmond A (1994) Mol Cell Biol 14(1): 791-802
    › Primary publication · 8264646 (PubMed) · PMC358427 (PubMed Central)
  142. Activation of protein kinase C enhances the phosphorylation of the type B interleukin-8 receptor and stimulates its degradation in non-hematopoietic cells. Mueller SG, Schraw WP, Richmond A (1995) J Biol Chem 270(18): 10439-48
    › Primary publication · 7737978 (PubMed)
  143. Melanoma growth stimulatory activity signaling through the class II interleukin-8 receptor enhances the tyrosine phosphorylation of Crk-associated substrate, p130, and a 70-kilodalton protein. Schraw W, Richmond A (1995) Biochemistry 34(42): 13760-7
    › Primary publication · 7577968 (PubMed)
  144. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. Nanney LB, Mueller SG, Bueno R, Peiper SC, Richmond A (1995) Am J Pathol 147(5): 1248-60
    › Primary publication · 7485389 (PubMed) · PMC1869526 (PubMed Central)
  145. HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene. Wood LD, Farmer AA, Richmond A (1995) Nucleic Acids Res 23(20): 4210-9
    › Primary publication · 7479086 (PubMed) · PMC307364 (PubMed Central)
  146. Purification of a mouse embryo extract component which enhances chondrogenesis in vitro. Richmond A, Elmer WA (1980) Dev Biol 76(2): 366-83
    › Primary publication · 6893034 (PubMed)
  147. Metabolic approaches to cancer cachexia. Lawson DH, Richmond A, Nixon DW, Rudman D (1982) Annu Rev Nutr : 277-301
    › Primary publication · 6821191 (PubMed)
  148. Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Richmond A, Lawson DH, Nixon DW, Stevens JS, Chawla RK (1983) Cancer Res 43(5): 2106-12
    › Primary publication · 6600964 (PubMed)
  149. Elevated plasma and urinary guanosine 3':5'-monophosphate and increased production rate in patients with neoplastic diseases. Chawla RK, Shlaer SM, Lawson DH, Murray TG, Schmidt F, Shoji M, Nixon DW, Richmond A, Rudman D (1980) Cancer Res 40(11): 3915-20
    › Primary publication · 6258769 (PubMed)
  150. In vitro growth promotion in human malignant melanoma cells by fibroblast growth factor. Richmond A, Lawson DH, Nixon DW, Stevens JS, Chawla RK (1982) Cancer Res 42(8): 3175-80
    › Primary publication · 6212117 (PubMed)
  151. Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma. Lawson DH, Nixon DW, Black ML, Tindall GT, Barnes DA, Faraj BA, Ali FM, Camp VM, Richmond A (1983) Cancer 51(8): 1541-5
    › Primary publication · 6186359 (PubMed)
  152. Effect of plasma inter-alpha trypsin inhibitor and cancer-related glycoprotein EDC1 on phytohemagglutinin-induced thymidine uptake in lymphocytes. Chawla RK, Lawson DH, Richmond A, Rudman D (1980) Cancer Res 40(11): 4187-91
    › Primary publication · 6162547 (PubMed)
  153. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Richmond A, Lawson DH, Nixon DW, Chawla RK (1985) Cancer Res 45(12 Pt 1): 6390-4
    › Primary publication · 3864531 (PubMed)
  154. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas. Richmond A, Fine R, Murray D, Lawson DH, Priest JH (1986) J Invest Dermatol 86(3): 295-302
    › Primary publication · 3745955 (PubMed)
  155. Preparation of a monoclonal antibody to a melanoma growth-stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells. Lawson DH, Thomas HG, Roy RG, Gordon DS, Chawla RK, Nixon DW, Richmond A (1987) J Cell Biochem 34(3): 169-85
    › Primary publication · 3611199 (PubMed)
  156. Separation of melanoma growth stimulatory activity and human type-alpha transforming growth factor. Richmond A, Thomas HG, Roy RG (1987) Methods Enzymol : 112-26
    › Primary publication · 3479673 (PubMed)
  157. Purification of melanoma growth stimulatory activity. Richmond A, Thomas HG (1986) J Cell Physiol 129(3): 375-84
    › Primary publication · 3465735 (PubMed)
  158. High yield purification of melanoma growth stimulatory activity. Thomas HG, Richmond A (1988) Mol Cell Endocrinol 57(1-2): 69-76
    › Primary publication · 3396757 (PubMed)
  159. Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution. Richmond A, Thomas HG (1988) J Cell Biochem 36(2): 185-98
    › Primary publication · 3356754 (PubMed)
  160. Immunoaffinity purification of melanoma growth stimulatory activity. Thomas HG, Richmond A (1988) Arch Biochem Biophys 260(2): 719-24
    › Primary publication · 3341763 (PubMed)
  161. Chromosome and growth factor abnormalities in melanoma. Priest JH, Phillips CN, Wang Y, Richmond A (1988) Cancer Genet Cytogenet 35(2): 253-62
    › Primary publication · 3141038 (PubMed)
  162. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. Richmond A, Balentien E, Thomas HG, Flaggs G, Barton DE, Spiess J, Bordoni R, Francke U, Derynck R (1988) EMBO J 7(7): 2025-33
    › Primary publication · 2970963 (PubMed) · PMC454478 (PubMed Central)
  163. Growth factor modulation of melanoma growth stimulatory activity mRNA expression in human malignant melanoma cells correlates with cell growth. Bordoni R, Thomas G, Richmond A (1989) J Cell Biochem 39(4): 421-8
    › Primary publication · 2722970 (PubMed)
  164. Nucleotide sequence of the human melanoma growth stimulatory activity (MGSA) gene. Baker NE, Kucera G, Richmond A (1990) Nucleic Acids Res 18(21): 6453
    › Primary publication · 2129556 (PubMed) · PMC332569 (PubMed Central)
  165. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. Bordoni R, Fine R, Murray D, Richmond A (1990) J Cell Biochem 44(4): 207-19
    › Primary publication · 2095366 (PubMed)
  166. The pathogenic role of growth factors in melanoma. Richmond A (1991) Semin Dermatol 10(3): 246-55
    › Primary publication · 1931574 (PubMed)
  167. Effects of MGSA/GRO alpha on melanocyte transformation. Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A (1991) Oncogene 6(7): 1115-24
    › Primary publication · 1861861 (PubMed)
  168. Purification and characterization of recombinant melanoma growth stimulating activity. Thomas HG, Han JH, Balentien E, Derynck R, Bordoni R, Richmond A (1991) Methods Enzymol : 373-83
    › Primary publication · 1857230 (PubMed)
  169. The melanoma growth stimulatory activity receptor consists of two proteins. Ligand binding results in enhanced tyrosine phosphorylation. Cheng QC, Han JH, Thomas HG, Balentien E, Richmond A (1992) J Immunol 148(2): 451-6
    › Primary publication · 1729365 (PubMed)